Lancet Infectious Diseases

Article	Citations
An interactive web-based dashboard to track COVID-19 in real time	7266
Estimates of the severity of coronavirus disease 2019: a model-based analysis	2568
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study	2428
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study	2368
Early dynamics of transmission and control of COVID-19: a mathematical modelling study	1632
Viral load of SARS-CoV-2 in clinical samples	1265
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study	1210
Viral dynamics in mild and severe cases of COVID-19	1186
A minimal common outcome measure set for COVID-19 clinical research	977
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	964
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study	873
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics	849
Clinical and virological data of the first cases of COVID-19 in Europe: a case series	844
Real estimates of mortality following COVID-19 infection	818
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	818
COVID-19: combining antiviral and anti-inflammatory treatments	810
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study	795
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Co	795
Convalescent plasma as a potential therapy for COVID-19	716
A clinical case definition of post-COVID-19 condition by a Delphi consensus	633
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study	629
Scientific and ethical basis for social-distancing interventions against COVID-19	621
Clinical features and management of human monkeypox: a retrospective observational study in the UK	620
Can we contain the COVID-19 outbreak with the same measures as for SARS?	614
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study	585

Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study	568
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study	534
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study	520
COVID-19 and multisystem inflammatory syndrome in children and adolescents	518
Genomic evidence for reinfection with SARS-CoV-2: a case study	506
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study	500
The value of antimicrobial peptides in the age of resistance	478
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance	477
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study	473
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	457
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study	456
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	455
Asymptomatic cases in a family cluster with SARS-CoV-2 infection	434
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study	431
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2	420
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation	389
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	382
COVID-19 and medical education	374
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical	363
Stigma during the COVID-19 pandemic	344
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series	338
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult	332
The many estimates of the COVID-19 case fatality rate	328
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study	325
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study	320
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries	319
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study	317
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study	307
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison	291
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2	291
Exaggerated risk of transmission of COVID-19 by fomites	288
The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017	267
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study	267
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial	263
The COVID-19 infodemic	260
COVID-19 pneumonia: what has CT taught us?	249
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis	248
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people	240
Serology testing in the COVID-19 pandemic response	234
Smell and taste dysfunction in patients with COVID-19	233
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England	224
Long-term consequences of COVID-19: research needs	220
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised	217
Taking the right measures to control COVID-19	214
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT	211
Covert COVID-19 and false-positive dengue serology in Singapore	210
Scaling up COVID-19 rapid antigen tests: promises and challenges	208
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial	206
SARS-CoV-2: virus dynamics and host response	206
Willingness to vaccinate against COVID-19 in Australia	203

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	201
Connecting clusters of COVID-19: an epidemiological and serological investigation	200
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial	197
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data	191
Open access epidemiological data from the COVID-19 outbreak	188
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study	187
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	186
COVID-19 in Latin America	184
COVID-19 in children: the link in the transmission chain	182
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont	182
Intention to vaccinate against COVID-19 in Australia	181
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study	179
Monitoring approaches for health-care workers during the COVID-19 pandemic	176
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis	175
Likelihood of survival of coronavirus disease 2019	171
The indirect impact of COVID-19 on women	170
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study	170
The important role of serology for COVID-19 control	170
What reinfections mean for COVID-19	163
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri	162
Baricitinib for COVID-19: a suitable treatment?	161
COVID-19 with spontaneous pneumomediastinum	161
Current gaps in sepsis immunology: new opportunities for translational research	161
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study	160
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design	160
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study	158
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial	157
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study	157
The first 2019 novel coronavirus case in Nepal	156
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19	154
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis	152
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity	148
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study	147
Global shortage of personal protective equipment	147
The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later	145
Antimalarial drug resistance in Africa: the calm before the storm?	145
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard	143
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study	142
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	142
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial	141
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study	141
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study	139
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis	137
The global incidence and diagnosis of fungal keratitis	137
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study	136
Guidelines for pregnant women with suspected SARS-CoV-2 infection	134
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study	132
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression	127
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis	126
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis	124
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding	123
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	122
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis	121
Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies	120
Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis	120
China's successful control of COVID-19	119
Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study	119
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and	118
Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines	117
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms	117
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study	117
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies	116
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav	116
Pandemic potential of 2019-nCoV	116
COVID-19 disrupts vaccine delivery	115
Estimating case fatality rates of COVID-19	115
Bell's palsy and SARS-CoV-2 vaccines	114
Monkeypox outbreaks outside endemic regions: scientific and social priorities	113
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial	113
Concerns and motivations about COVID-19 vaccination	113
Rural areas at risk during COVID-19 pandemic	113
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study	113
Estimation of COVID-19 outbreak size in Italy	111
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions	111
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial	109
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial	109
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England	108
Hospitalisation among vaccine breakthrough COVID-19 infections	107
Protective immunity after recovery from SARS-CoV-2 infection	105
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	105

Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US	104
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study	104
Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation	101
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study	100
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled	100
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2	100
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study	99
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 tria	98
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis	97
Vaccinology: time to change the paradigm?	97
A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China	96
A case of imported Monkeypox in Singapore	95
RT-PCR for SARS-CoV-2: quantitative versus qualitative	95
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study	95
The status of tuberculosis vaccine development	94
Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial	93
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial	93
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time	92
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	92
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series	91
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland	89
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis	88
Understanding COVID-19: what does viral RNA load really mean?	87
Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool	87
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe	85
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation	84
Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study	84
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5	83
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study	83
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial	83
The world's largest COVID-19 vaccination campaign	81
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study	81
The place for remdesivir in COVID-19 treatment	81
Outbreak of coronavirus disease 2019	81
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration	80
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study	80
COVID-19 human challenge studies: ethical issues	79
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies	79
Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017	79
Lung fibrosis: an undervalued finding in COVID-19 pathological series	79
Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017	78
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice	78
Epidemic preparedness in urban settings: new challenges and opportunities	78
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB	78
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial	78
SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients	78
Hydroxychloroquine prophylaxis for COVID-19 contacts in India	77
Monoclonal antibody therapies against SARS-CoV-2	77
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	77
Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data	76
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial	75
Prevention of monkeypox with vaccines: a rapid review	75
Management of pregnant women infected with COVID-19	74
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020	74
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study	74
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies	74
Zoonotic spillover infections with Borna disease virus 1 leading to fatal human encephalitis, 1999–2019: an epidemiological investigation	73
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19	73
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat	73
Genomic-informed pathogen surveillance in Africa: opportunities and challenges	73
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study	73
Disease X: accelerating the development of medical countermeasures for the next pandemic	73
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s	72
Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study	72
Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study	71
Antibiotic exposure among children younger than 5 years in low-income and middle-income countries: a cross-sectional study of nationally representative facility-based and household-based surveys	71
Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study	71
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	71
The scientific and ethical feasibility of immunity passports	70
The intersection of COVID-19 and mental health	70
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review	70
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial	70
Assessment of non-prescription antibiotic dispensing at community pharmacies in China with simulated clients: a mixed cross-sectional and longitudinal study	70
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study	69
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5	69
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3	68
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO	68
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An	67
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study	67
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial	66
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study	66
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant	66
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial	66
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase	66
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial	66
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study	65
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices	64
Gaps in India's preparedness for COVID-19 control	63
Effect of infectious disease consultation on mortality and treatment of patients with candida bloodstream infections: a retrospective, cohort study	63
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis	62
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study	62
Improving the estimation of the global burden of antimicrobial resistant infections	62
CoronaVac induces lower neutralising activity against variants of concern than natural infection	61
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac	61
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis	61
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective	61
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM	60
The state of vaccine safety science: systematic reviews of the evidence	60
Emergence of the Asian lineage of Zika virus in Angola: an outbreak investigation	60
Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study	59
Persistence of IgG response to SARS-CoV-2	59
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review	59
Hand hygiene in health care: 20 years of ongoing advances and perspectives	59
Re-examining causes of surgical site infections following elective surgery in the era of asepsis	58
Game consumption and the 2019 novel coronavirus	58
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-infer	57
Models of gonorrhoea transmission from the mouth and saliva	57
Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study	57
100 years of Mycobacterium bovis bacille Calmette-Guérin	57
Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis	57
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach	57
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll	57
Hospitalisation associated with SARS-CoV-2 delta variant in Denmark	56
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation	56
A case of SARS-CoV-2 reinfection in Ecuador	56
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study	55
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis	55
Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis	55
The origin of SARS-CoV-2	55
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	55
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study	54
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial	54
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study	54
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak	54
Associations between phone mobility data and COVID-19 cases	53
COVID-19 vaccine equity and booster doses	53
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study	53
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse	52
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati	52
Viral loads in clinical samples of men with monkeypox virus infection: a French case series	51
Inclusion of pregnant women in COVID-19 vaccine development	51
Antibiotic prescribing in general practice during COVID-19	51
CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants	50
Cavitary tuberculosis: the gateway of disease transmission	50
The role of schools and school-aged children in SARS-CoV-2 transmission	50
Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China	50
The importance of understanding the infectious microenvironment	50
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial	49
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial	49
Initiation of a new infection control system for the COVID-19 outbreak	49
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21	49
Global COVID-19 vaccine inequity	48
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study	48
A governance framework for development and assessment of national action plans on antimicrobial resistance	48
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort	47

Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, pha	47
Effectiveness of BNT162b2 against COVID-19 in adolescents	46
From China: hope and lessons for COVID-19 control	46
Baricitinib for COVID-19: a suitable treatment? – Authors' reply	46
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis	46
Increased risk of hospitalisation and death with the delta variant in the USA	46
Global increases in antibiotic consumption: a concerning trend for WHO targets	45
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials	45
Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA	45
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis	45
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation	45
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity	44
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants	44
Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study	44
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial	44
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	44
SARS-CoV-2 incidence and vaccine escape	44
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies	43
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?	43
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study	43
Dental procedure aerosols and COVID-19	42
Impact of contact tracing on SARS-CoV-2 transmission	42
Quantifying the global number of tuberculosis survivors: a modelling study	42
COVID-19, a pandemic or not?	41
Long-term survival and cause-specific mortality of patients newly diagnosed with tuberculosis in São Paulo state, Brazil, 2010–15: a population-based, longitudinal study	41
India's COVID-19 vaccination drive: key challenges and resolutions	41
The public health crisis of underimmunisation: a global plan of action	41
Decarceration and community re-entry in the COVID-19 era	41
Plasmodium falciparum resistance to piperaquine driven by PfCRT	41
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial	41
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark	40
Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial	40
Assessment of patients who tested positive for COVID-19 after recovery	40
Vaccine hesitancy in the COVID-19 era	40
Challenges of coronavirus disease 2019	40
Preparedness for emerging epidemic threats: a Lancet Infectious Diseases Commission	40
Prevention of host-to-host transmission by SARS-CoV-2 vaccines	40
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection	40
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial	40
The complexities of SARS-CoV-2 serology	39
What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?	39
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study	39
A need for open public data standards and sharing in light of COVID-19	39
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology a	39
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study	39
Silent COVID-19: what your skin can reveal	39
Recent successes in therapeutics for Ebola virus disease: no time for complacency	39
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study	39
Estimation of COVID-19 burden in Egypt	38
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial	38
The first Vietnamese case of COVID-19 acquired from China	38
Estimating case fatality rates of COVID-19	38
Unprecedented rise in dengue outbreaks in Bangladesh	38
Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study	38
Evasion of neutralising antibodies by omicron sublineage BA.2.75	38
Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infectio	37
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach	37
Long-term impact of an educational antimicrobial stewardship programme in primary care on infections caused by extended-spectrum β-lactamase-producing Escherichia coli in the community: an interrupted	37
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, p	36
Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK	36
Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis	36
T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study	36
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study	36
Change in obstetric attendance and activities during the COVID-19 pandemic	35
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens	35
Limitations of using mobile phone data to model COVID-19 transmission in the USA	35
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	35
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudin	34
COVID-19 screening of health-care workers in a London maternity hospital	34
CT screening for early diagnosis of SARS-CoV-2 infection	34
Ct values and infectivity of SARS-CoV-2 on surfaces	34
Mediastinal lymphadenopathy in patients with severe COVID-19	34
COVID-19: the deadly threat of misinformation	33
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial	33
The first WHO global survey on infection prevention and control in health-care facilities	33
Global outbreak research: harmony not hegemony	33
Mortality and adverse joint outcomes following septic arthritis of the native knee: a longitudinal cohort study of patients receiving arthroscopic washout	33
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial	33
Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic	33
Who is most likely to be infected with SARS-CoV-2?	33
Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study	33
The arrival of Sputnik V	33
Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review	33
Asymptomatic SARS-CoV-2 infection	33
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	33
A decentralised point-of-care testing model to address inequities in the COVID-19 response	33
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials	32
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019	32
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial	32
SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study	32
Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study	32
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a random	32
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5	32
Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study	32
STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies	32
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negati	32
No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy	32
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	32
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant	31
Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study	31
Toward a clinically based classification of disease severity for paediatric COVID-19	31
Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study	31
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab	31
Congenital syphilis, the great imitator—case report and review	31
Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses	31
Outbreak investigation for COVID-19 in northern Vietnam	31
Risking further COVID-19 waves despite vaccination	31
Measles epidemic in Samoa and other Pacific islands	31
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial	30
Implications of non-prescription antibiotic sales in China	30
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019	30
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study	30
Evidence for action: a One Health learning platform on interventions to tackle antimicrobial resistance	30
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	30
Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis	30
Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities	30
Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study	30
Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies	30
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial	29
Elimination of COVID-19: what would it look like and is it possible?	29
Persistence of US measles risk due to vaccine hesitancy and outbreaks abroad	29
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases	29
Targeting COVID-19 interventions towards migrants in humanitarian settings	29
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant	29
COVID-19 among American Indians and Alaska Natives	29
Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control	29
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward	29
Banning colistin in feed additives: a small step in the right direction	29
A household-level score to predict the risk of tuberculosis among contacts of patients with tuberculosis: a derivation and external validation prospective cohort study	29
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	28
(Inter)nationalising the antibiotic research and development pipeline	28
Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study	28
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study	28
Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum β-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiorit	28
Obstacles to COVID-19 control in east Africa	28
Community burden and transmission of acute gastroenteritis caused by norovirus and rotavirus in the Netherlands (RotaFam): a prospective household-based cohort study	28
Pregnancy and breastfeeding in the context of Ebola: a systematic review	28
Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study	28
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study	27
Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India	27
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	27
Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays	27
Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial	27
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study	27
Changes in epilepsy burden after onchocerciasis elimination in a hyperendemic focus of western Uganda: a comparison of two population-based, cross-sectional studies	27
Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study	27
Measles eradication—retreating is not an option	27
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial	27
Prevention of the cytokine storm in COVID-19	27
Equitable distribution of COVID-19 vaccines	27
Rolling out COVID-19 antigen rapid diagnostic tests: the time is now	27
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial	27
Food for thought: addressing undernutrition to end tuberculosis	26
Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study	26
Bacteriophages: it's a medicine, Jim, but not as we know it	26
Protecting workers aged 60–69 years from COVID-19	26
The importance of enterovirus surveillance in a post-polio world	26
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis	26
Lassa virus circulating in Liberia: a retrospective genomic characterisation	26
Treponema pallidum detection in lesion and non-lesion sites in men who have sex with men with early syphilis: a prospective, cross-sectional study	26
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind,	26
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial	26
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 20	26
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned	26
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics	26
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults	26
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-con	26
Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data	25
A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study	25
Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study	25
Bell's palsy and SARS-CoV-2 vaccines—an unfolding story	25
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlle	25
Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey	25
Screening and vaccination against COVID-19 to minimise school closure: a modelling study	25
Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential	25
Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial	25
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study	25
COVID-19 in Africa: half a year later	25
Sustained transmission of Ebola in new locations: more likely than previously thought	25
What does 95% COVID-19 vaccine efficacy really mean?	25
New nomenclature for mpox (monkeypox) and monkeypox virus clades	25
Long COVID has exposed medicine's blind-spot	25
HIV infection predominantly affecting children in Sindh, Pakistan, 2019: a cross-sectional study of an outbreak	25
The origin of SARS-CoV-2 variants of concern	25
The long shadow post-tuberculosis	24
Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study	24
Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection	24
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial	24
The first COVID-19 case in Afghanistan acquired from Iran	24
Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy	24
Kinetics and seroprevalence of SARS-CoV-2 antibodies in children	24
Technical assessment of the neonatal early-onset sepsis risk calculator	24
Sensitive diagnostic tools and targeted drug administration strategies are needed to eliminate schistosomiasis	24
Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study	24
Booster shots for COVID-19—the debate continues	24
Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix?	24
Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpo	24
The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out	24
Inactivated COVID-19 vaccines to make a global impact	24
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	23